The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Both organisations enter into a long- term collaboration to expand patient access in India
The company is confident of addressing the concern raised by the USFDA
Subscribe To Our Newsletter & Stay Updated
